Return to Clinical Trials Search Results

Randomized, Phase II, Double-Blind, Placebo-Controlled Trial of Conventional Chemoradiation and Adjuvant Temozolomide Plus Cediranib Versus Conventional Chemoradiation and Adjuvant Temozolomide Plus Placebo in Patients With Newly Diagnosed Glioblastoma

Primary To determine if the addition of cediranib to chemoradiation treatment enhances treatment efficacy as measured by the 6-month progression-free survival rate Secondary To determine if the addition of cediranib to chemoradiation treatment enhances treatment efficacy as measured by overall survival. To determine if the addition of cediranib to chemoradiation treatment enhances treatment efficacy as measured by progression-free survival. To determine if there is an association between tumor MGMT gene methylation status and treatment response and outcome. To compare and record the toxicities of the cediranib + chemoradiation arm versus the chemoradiation arm. To evaluate whether 6-month progression-free survival is associated with overall survival

Primary To determine if the addition of cediranib to chemoradiation treatment enhances treatment efficacy as measured by the 6-month progression-free survival rate Secondary To determine if the addition of cediranib to chemoradiation treatment enhances treatment efficacy as measured by overall survival. To determine if the addition of cediranib to chemoradiation treatment enhances treatment efficacy as measured by progression-free survival. To determine if there is an association between tumor MGMT gene methylation status and treatment response and outcome. To compare and record the toxicities of the cediranib + chemoradiation arm versus the chemoradiation arm. To evaluate whether 6-month progression-free survival is associated with overall survival